Literature DB >> 21106780

Protective immunity induced by Toxoplasma gondii rhoptry protein 16 against toxoplasmosis in mice.

Zi-Guo Yuan1, Xiu-Xiang Zhang, Xian-Hui He, Eskild Petersen, Dong-Hui Zhou, Yong He, Rui-Qing Lin, Xiu-Zhen Li, Xu-Li Chen, Xiao-Ru Shi, Xiu-Ling Zhong, Bing Zhang, Xing-Quan Zhu.   

Abstract

Toxoplasma gondii can infect a large variety of domestic and wild animals and human beings, sometimes causing severe pathology. Rhoptries are involved in T. gondii invasion and host cell interaction and have been implicated as important virulence factors. In this study, we constructed a DNA vaccine expressing rhoptry protein 16 (ROP16) of T. gondii and evaluated the immune responses it induced in Kunming mice. The gene sequence encoding ROP16 was inserted into the eukaryotic expression vector pVAX I. We immunized Kunming mice intramuscularly. After immunization, we evaluated the immune response using a lymphoproliferative assay, cytokine and antibody measurements, and the survival times of mice challenged lethally. The results showed that mice immunized with pVAX-ROP16 developed a high level of specific antibody responses against T. gondii ROP16 expressed in Escherichia coli, a strong lymphoproliferative response, and significant levels of gamma interferon (IFN-γ), interleukin-2 (IL-2), IL-4, and IL-10 production compared with results for other mice immunized with either empty plasmid or phosphate-buffered saline, respectively. The results showed that pVAX-ROP16 induces significant humoral and cellular Th1 immune responses. After lethal challenge, the mice immunized with pVAX-ROP16 showed a significantly (P < 0.05) prolonged survival time (21.6 ± 9.9 days) compared with control mice, which died within 7 days of challenge. Our data demonstrate, for the first time, that ROP16 triggers a strong humoral and cellular response against T. gondii and that ROP16 is a promising vaccine candidate against toxoplasmosis, worth further development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106780      PMCID: PMC3019779          DOI: 10.1128/CVI.00312-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  39 in total

Review 1.  DNA vaccine strategies: candidates for immune modulation and immunization regimens.

Authors:  Nicole A Doria-Rose; Nancy L Haigwood
Journal:  Methods       Date:  2003-11       Impact factor: 3.608

Review 2.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  [Construction of monovalent and compound nucleic acid vaccines against Toxoplasma gondii with gene encoding p30].

Authors:  Ting-ting Yang; Shen-yi He; Hua Jiang; Qin-min Gu; Hua Cong; Huai-yu Zhou; Jia-qin Zhang; Ying Li; Qun-li Zhao
Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  2005-02-28

4.  Protective effect of a naked DNA vaccine cocktail against lethal toxoplasmosis in mice.

Authors:  Alberto Fachado; Alexandro Rodriguez; Sergio O Angel; Diamar C Pinto; Iviane Vila; Armando Acosta; Regina R Amendoeira; Joseli Lannes-Vieira
Journal:  Vaccine       Date:  2003-03-28       Impact factor: 3.641

Review 5.  Toxoplasmic encephalitis in AIDS.

Authors:  B J Luft; J S Remington
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

6.  Comparison of cholera toxin A2/B and murine interleukin-12 as adjuvants of Toxoplasma multi-antigenic SAG1-ROP2 DNA vaccine.

Authors:  Mingfu Xue; Shenyi He; Jie Zhang; Yuling Cui; Yuan Yao; Huaxin Wang
Journal:  Exp Parasitol       Date:  2008-03-23       Impact factor: 2.011

7.  Toxoplasmosis: the first commercial vaccine.

Authors:  D Buxton
Journal:  Parasitol Today       Date:  1993-09

8.  The Toxoplasma gondii bradyzoite antigens BAG1 and MAG1 induce early humoral and cell-mediated immune responses upon human infection.

Authors:  Manlio Di Cristina; Paola Del Porto; Wilma Buffolano; Elisa Beghetto; Andrea Spadoni; Silvia Guglietta; Enza Piccolella; Franco Felici; Nicola Gargano
Journal:  Microbes Infect       Date:  2004-02       Impact factor: 2.700

Review 9.  Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection.

Authors:  E Y Denkers; R T Gazzinelli
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

10.  Immune response induced by recombinant Mycobacterium bovis BCG expressing ROP2 gene of Toxoplasma gondii.

Authors:  Hongfa Wang; Quan Liu; Keyi Liu; Weixia Zhong; Shengyan Gao; Li Jiang; Na An
Journal:  Parasitol Int       Date:  2007-05-10       Impact factor: 2.230

View more
  25 in total

1.  Evaluation of the Protective Effect of Deoxyribonucleic Acid Vaccines Encoding Granule Antigen 2 and 5 Against Acute Toxoplasmosis in BALB/c Mice.

Authors:  Xiao Teng Ching; Mun Yik Fong; Yee Ling Lau
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

2.  Vaccination with a DNA vaccine coding for perforin-like protein 1 and MIC6 induces significant protective immunity against Toxoplasma gondii.

Authors:  Hai-Kuo Yan; Zi-Guo Yuan; Hui-Qun Song; Eskild Petersen; Yang Zhou; Di Ren; Dong-Hui Zhou; Hao-Xin Li; Rui-Qing Lin; Gui-Lian Yang; Xing-Quan Zhu
Journal:  Clin Vaccine Immunol       Date:  2012-02-29

3.  Evaluation of immune responses in mice after DNA immunization with putative Toxoplasma gondii calcium-dependent protein kinase 5.

Authors:  Nian-Zhang Zhang; Si-Yang Huang; Ying Xu; Jia Chen; Jin-Lei Wang; Wei-Peng Tian; Xing-Quan Zhu
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

4.  Protective efficacy of a Toxoplasma gondii rhoptry protein 13 plasmid DNA vaccine in mice.

Authors:  Pei-Yuan Wang; Zi-Guo Yuan; Eskild Petersen; Jie Li; Xiu-Xiang Zhang; Xiu-Zhen Li; Hao-Xin Li; Zhi-Cheng Lv; Tian Cheng; Di Ren; Gui-Lian Yang; Rui-Qing Lin; Xing-Quan Zhu
Journal:  Clin Vaccine Immunol       Date:  2012-09-26

Review 5.  REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII.

Authors:  Rosalie C Warner; Ryan C Chapman; Brianna N Davis; Paul H Davis
Journal:  J Parasitol       Date:  2021-11-01       Impact factor: 1.276

6.  Toxoplasma gondii: immune response and protective efficacy induced by ROP16/GRA7 multicomponent DNA vaccine with a genetic adjuvant B7-2.

Authors:  Qi Liu; Fuwu Wang; Guan Wang; Qunli Zhao; Juan Min; Shuai Wang; Hua Cong; Ying Li; Shenyi He; Huaiyu Zhou
Journal:  Hum Vaccin Immunother       Date:  2013-10-07       Impact factor: 3.452

7.  Interleukin-10 Serum Levels after Vaccination with In Vivo Prepared Toxoplasma gondii Excreted/Secreted Antigens.

Authors:  Seyed Hossein Abdollahi; Fateme Ayoobi; Hossein Khorramdelazad; Gholamhossein Hassanshahi; Behzad Nasiri Ahmadabadi; Mohammadtaghi Rezayati; Ali Ravary; Ali Shamsizadeh; Mohammad Kazemi Arababadi
Journal:  Oman Med J       Date:  2013-03

8.  Protective immune response in BALB/c mice induced by DNA vaccine of the ROP8 gene of Toxoplasma gondii.

Authors:  Sonaimuthu Parthasarathy; Mun Yik Fong; Kalyanasundaram Ramaswamy; Yee Ling Lau
Journal:  Am J Trop Med Hyg       Date:  2013-03-18       Impact factor: 2.345

9.  Protective efficacy of recombinant canine adenovirus type-2 expressing TgROP18 (CAV-2-ROP18) against acute and chronic Toxoplasma gondii infection in mice.

Authors:  Xiu-Zhen Li; Xiao-Hu Wang; Li-Jun Xia; Ya-Biao Weng; Jorge A Hernandez; Li-Qing Tu; Lu-Tao Li; Shou-Jun Li; Zi-Guo Yuan
Journal:  BMC Infect Dis       Date:  2015-03-04       Impact factor: 3.090

10.  Intranasal immunisation with recombinant Toxoplasma gondii actin partly protects mice against toxoplasmosis.

Authors:  Li-Tian Yin; Hai-Xia Hao; Hai-Long Wang; Jian-Hong Zhang; Xiao-Li Meng; Guo-Rong Yin
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.